|1.||Fu, M L: 2 articles (10/2001 - 01/2001)|
|2.||Matsui, S: 2 articles (10/2001 - 01/2001)|
|3.||Góngora-Alfaro, José L: 1 article (06/2014)|
|4.||Alvarez-Cervera, Fernando J: 1 article (06/2014)|
|5.||Bata-García, José L: 1 article (06/2014)|
|6.||Erosa-Rivero, Helena B: 1 article (06/2014)|
|7.||Heredia-López, Francisco J: 1 article (06/2014)|
|8.||Liao, Ching-Fong: 1 article (11/2002)|
|9.||Hsieh, Dennis Jine-Yuan: 1 article (11/2002)|
|10.||Hayase, M: 1 article (10/2001)|
10/01/1991 - "We conclude that AF-DX 116 may be a useful drug for the treatment of bradycardia. "
05/05/1986 - "AF-DX 116, for its pronounced cardioselectivity, may have a therapeutic potential in the treatment of sinus bradycardia."
01/01/1991 - "When marked bradycardia (approximately 75% of control value) was reached, rats were given atropine sulfate (2 mg/kg, i.p.) or AF-DX 116 (20 mg/kg, i.p.). "
05/05/1986 - "In the conscious dog intravenous AF-DX 116 increased basal heart rate, and completely reversed the reflex bradycardia induced by clonidine. "
05/05/1986 - "In pithed rats AF-DX 116 inhibits vagally-induced bradycardia, an M2 response, (ED50 32 micrograms/kg i.v.) in preference to the M1-mediated pressor response to McN-A-343 (ED50 211 micrograms/kg i.v.). "
|3.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/01/2001 - "This study indicates that anti-beta1-adrenoceptor and anti-M2-muscarinic receptor antibodies are of pathogenic importance in the development of human dilated cardiomyopathy, and that beta-adrenoceptor blockade, bisoprolol, and M2-muscarinic receptor antagonist, otenzepad, might be clinically useful for treatment of dilated cardiomyopathy."
01/01/1994 - "AF-DX 116 induced a tachycardia without a decrease of salivary flow in agreement with its selectivity profile (M2 > M1 > M3). "
02/01/1993 - "Finally, AF-DX 116, at doses inducing marked tachycardia, had a minor intestinal effect and no mydriatic effect. "
02/01/1991 - "AF-DX 116 (10-100 micrograms/kg) had no effect on the preganglionic SNS-induced tachycardia. "
12/01/1989 - "AF-DX 116 induces a tachycardia together with an increased salivary flow in agreement with its selectivity profile (M2 greater than M1 greater than M3). "
09/01/1994 - "Aconitine (0.16-0.25 microM) induced tachyarrhythmia in right atria was attenuated by quinidine (1 microM), atropine (8.6 microM) and AF-DX 116 (8.6 microM), suggesting that aconitine activates sodium channels and muscarinic receptors. "
01/01/1991 - "Muscarinic receptors in N1E 115 mouse neuroblastoma cells were characterized by competition binding experiments using three agonists and five antagonists, including 4-DAMP and AF-DX 116, and by studying the effect of agonist stimulation on the cellular cAMP and cGMP content. "
07/31/1989 - "The cardioselective muscarinic antagonist, AF-DX 116 [11[2-[(diethyl-amino)-methyl]-O-1-piperidinyl]-5,11-dihydro-6H-pyrido- [2,3-b][1,4]-benzodiazepine-6-one), was weak at blocking the M2 muscarinic receptor-mediated inhibition of cyclic adenosine monophosphate (cAMP) formation in mouse neuroblastoma cells (clone N1E-115). "
|8.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|10.||Gallamine Triethiodide (Gallamine)
|3.||Induced Hyperthermia (Thermotherapy)